1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Cures Within Reach runs what is, as far as published RFPs go, the clearest funding bridge between AI drug-repurposing predictions and actual patients. The program funds investigator-initiated proof-of-concept, phase I or phase IIA clinical trials that validate AI-driven drug-disease matches where the therapy in question is already an approved medication.
Awards are up to USD 100,000 including a mandatory 10 percent institutional match, with extra funds available for community engagement. The first cycle ran in 2025 and selected six validation trials; the 2026 cycle had a letter of intent deadline of 26 June 2026 and both the LOI and full proposal deadlines have now closed, with submissions under review.
The structural problem this addresses is real: AI models generate large numbers of plausible drug-disease matches, and almost none of them get clinically tested because no conventional funder wants to pay for a trial of an off-patent drug with no commercial sponsor.
Supporting data from any type of AI model is accepted, whether the model is owned by a nonprofit, academic, government or for-profit institution, and whether it is publicly open or accessible only through collaboration. Cures Within Reach states a preference for rare diseases and for off-patent therapies, though any unsolved disease area is eligible. Researchers should monitor the program page for the 2027 cycle.
Get alerted about grants like this
Get emailed when new opportunities from “Cures Within Reach, with lead funding from Biohub and co-funding from Lyda Hill Philanthropies” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Applications come from institutions conducting investigator-initiated clinical trials, and both United States and international research institutions are eligible with sites welcome in any country. Any unsolved disease area is eligible, with a stated preference for rare diseases. Both on-patent and off-patent repurposed therapies qualify, with a stated preference for off-patent therapies. The candidate therapy must already be an approved drug or biologic, and AI-generated data must form part of the preclinical support for the proposed trial; supporting data from any type of AI model is accepted, including models developed and controlled by nonprofit, academic, government or for-profit institutions and models that are either publicly open or accessible only via collaboration. Trials must be proof-of-concept, phase I or phase IIA. Awards are capped at USD 100,000 including a mandatory 10 percent institutional match, with additional funds available for community engagement. The 2026 cycle letter of intent deadline was 26 June 2026 and both LOI and full proposal stages are now closed with submissions under review. Applicants interested in the next cycle should confirm eligibility, match requirements, trial phase definitions and deadlines directly with Cures Within Reach before preparing materials. Confirm the full requirements in the official notice before applying.
The current listing shows grants of up to USD 100,000 per clinical trial, inclusive of a mandatory 10 percent institutional match, with additional funds available for community engagement activities. amount_min of 100,000 and amount_max of 100,000 reflect the single published award ceiling. This is deliberately small for a clinical trial, and the program works because it funds proof-of-concept and phase I or IIA trials of already-approved therapies where safety data exists and the incremental cost of a validation trial is low - the money buys clinical evidence, not drug development. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Cures Within Reach Clinical Trials to Validate AI-Driven Drug Repurposing 2026 Request for Proposals is funded by Cures Within Reach, with lead funding from Biohub and co-funding from Lyda Hill Philanthropies. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On August 26, 2026, NSF named the STC class of 2026: TEMPEST at Michigan State, GENIE at Northwestern, and a human-robot co-adaptation center at UT Austin. $90 million total, $6 million a year each. The 2023 class was four centers and $120 million. The award size is intact; the shelf space shrank 25 percent — and that is the number that should reshape how you plan a center proposal.
Read articleRejected SBIR proposal? Good — now you have reviewer feedback. Use it to address weaknesses, sharpen your aims, and resubmit stronger.
Read articleMaster the NIH resubmission process. Analyze Summary Statements, address reviewer critiques, and revise your grant proposal for funding success.
Read article